Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.

In the BRIGHT study, bendamustine plus rituximab was evaluated as a first-line treatment for indolent non-Hodgkin lymphoma or mantle cell lymphoma compared with a standard rituximab-chemotherapy ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

clonoSEQ testing for patients with MCL is currently available for clinical use as a laboratory-developed test performed at Adaptive's CLIA-certified lab in Seattle. clonoSEQ testing in MCL has also ...

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

Amneal and Shilpa are releasing Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous administration or ...

Boruzu is the first ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma ... Shilpa introduce Boruzu in US for cancer treatment" was originally created and published ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

Adaptive Biotechnologies (ADPT) announced that Palmetto GBA, a Medicare Administrative Contractor, MAC, that assesses diagnostic technologies ...

Imfinzi is approved in combination with gemcitabine and cisplatin as a neoadjuvant treatment for muscle ... use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).